profit from every $100 of sales.
$0$100
Zymeworks
$26.24-0.87% today
+41.8% in 1 year
1-year low $18.501-year high $31.46
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Zymeworks sold, what it kept, and what it did with the cash.
Sales went from $412 million in 2022 to $106 million in 2025, with -$81.1 million of profit last year.
SalesProfit
Zymeworks vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Zymeworks | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Zymeworks's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 412 | 76 | 76 | 106 | |
| – | – | – | – | |
| 130 | -138 | -120 | -93 | |
| 142 | -121 | -109 | -81 | |
| 124 | -119 | -123 | -81 | |
| 1.90 | -1.72 | -1.62 | -1.08 | |
| – | – | – | – | |
| 31.6% | -181.6% | -157.0% | -87.3% | |
| 30.1% | -156.1% | -160.8% | -76.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 649 | 581 | 463 | 347 |
| Cash | 401 | 158 | 66 | 41 |
| Total debt | 28 | 27 | 19 | 18 |
| Total liabilities | 156 | 116 | 124 | 78 |
| 493 | 465 | 339 | 269 | |
| 65 | 69 | 76 | 75 | |
| 19.8% | -22.2% | -26.5% | -25.5% | |
| 25.2% | -25.5% | -36.2% | -30.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 144 | -118 | -110 | -33 | |
| 13 | 4 | 3 | 2 | |
| 131 | -122 | -113 | -35 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 30 | 42 | |
| 4 | 8 | 18 | 28 |
Valuation
- –
- 22.1×
- –
- 0.0×
- 17.4×
- –
- –
- -1.9%
- -4.4%
- 0.0%
Profitability
- 94.4%
- -87.3%
- -76.6%
- -136.9%
- -0.0%
- -27.6%
- -0.2%
- -0.0%
- -0.0%
- 3,087.8%
Growth
- −36.4%
- –
- +69.5%
- –
- +9.6%
Financial health
- -0.3×
- 0.10
- 3.6%
- -55.2×
- 10.82
- 10.82
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 33%of 952
Bottom 4%of 884
Bottom 2%of 886
Bottom 29%of 987
What analysts expect
- Average price target
- $38.33
- Range
- $32.00 – $48.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.59 | -0.10 | −490.0% |
| Mar 2, 2026 | -0.55 | -0.35 | −57.1% |
| Nov 6, 2025 | -0.26 | -0.30 | +13.3% |
| Aug 7, 2025 | 0.03 | -0.52 | +105.8% |
| May 8, 2025 | -0.30 | -0.45 | +33.3% |
| Mar 5, 2025 | -0.31 | 0.01 | −3,200.0% |
| Oct 31, 2024 | -0.39 | -0.40 | +2.5% |
| Aug 1, 2024 | -0.49 | -0.42 | −17.4% |
News
Zymeworks early-stage results on ADC show anti-tumor activity in ovarian cancerSeeking Alpha · Oct 24, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
75Pass
Philip Fisher
39No pass
Peter Lynch
30No pass
Joel Greenblatt
2No pass
Charlie Munger
33No pass
Terry Smith
27No pass
Questions about Zymeworks
Is Zymeworks a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Zymeworks AI analysis
What does Zymeworks do?
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. It is in Biotechnology.
Does Zymeworks pay a dividend?
No. Zymeworks does not pay a dividend at the moment; in 2025 it returned $41.7 million to shareholders by buying back its own shares.
Is Zymeworks stock halal?
Yes. Zymeworks passes our halal screen: its business is permitted and its debt is 1.0% of its market value, under the 30% limit. How we check
How has Zymeworks stock done over the past year?
Up 41.8% over the past twelve months, to $26.24. It traded between $18.50 and $31.46 and is 16.6% below its high.
Who are Zymeworks's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Zymeworks's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.